Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
Sanofi Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...
Investing Snacks1d
Regeneron Hits a New Low—Wall Street Hits Snooze
Regeneron Pharmaceuticals just belly-flopped into a fresh 12-month low, trading as low as $640.28—Wall Street winced. Analyst ...
Investing Snacks2d
Regeneron Trimmed: Hedge Funds Snip the Biotech Giant
American Century Companies trimmed its stake in Regeneron Pharmaceuticals by 4.2% during Q4, selling nearly 31,000 shares and ...
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors
Regeneron Pharmaceuticals Inc. closed 47.64% short of its 52-week high of $1,211.20, which the company reached on August 27th.